Download PDF
Exp Clin Endocrinol Diabetes 1989; 93(2/03): 114-124
DOI: 10.1055/s-0029-1210844
Original

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Current Stage of Interleukin 2 Receptor Targeted Therapy1)

T. Diamantstein, J. W. Kupiec-Weglinski, T. B. Strom, N. L. Tilney
  • Institute of Immunology, Klinikum Steglitz, Free University Berlin (West), Surgical Research Laboratory, Harvard Medical School, Harvard-Thorndike Laboratory of the Beth Israel Hospital, Departments of Surgery and Medicine, Brigham, and Womens Hospital, and Beth Israel Hospital, Boston, USA
1) Supported in part by Deutsche Forschungsgemeinschaft (Di 152/8—3, Di 152/8—4) and by NIH Grant 5 RO1 AI 19071-13, Grant- in -Aid #861424 from the American Heart Association and Sandoz Inc.
Further Information

Publication History

1988

Publication Date:
16 July 2009 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The overview summarizes a new and selective form of immunosuppressive therapy by using anti-Interleukin-2 receptor monoclonal antibodies, which may soon become an important form of recipient treatment in organ/tissue transplantation or/and of patient treatment with autoimmune diseases.

Key Words

Interleukin 2 receptor - Monoclonal antibodies - Immunotherapy